1. Scrip

Challenges Linger As Chinese Firms Kick Off R&D Race (Pt.1)

 
• By Ying Huang

China's pharmaceutical industry is entering a critical period of transformation as it is losing its traditional price competitiveness in the international market and is now looking more to develop its potential as a force in original R&D. New development models and innovative firms have emerged in the country in recent years, and shared some of their strategies and challenges at a recent meeting in Shanghai.

In this first part of a two-part feature, a number of China bioventures outline their strategies for pursuing innovation as part of the country’s broader push towards a more R&D-based economy, and how they are looking to meet medical needs and grow their businesses amid remaining challenges.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Focus On Asia

More from Scrip